Not Yet Recruiting PHASE3 INTERVENTIONAL 2-arm
NCT07357675
A Clinical Trial To Investigate The Effect Of EA-230 On Hospital Length Of Stay In Patients With Coronary Artery Disease (CAD) Undergoing Coronary Artery Bypass Grafting (CABG) Surgery. (EasyBoost)
A Clinical Trial To Investigate The Effect Of EA-230 On Hospital Length of Stay In Patients With Coronary Artery Disease (CAD) Undergoing Coronary Artery Bypass Grafting (CABG) Surgery.
Sponsor: CR2O B.V.
Interventions
EA-230 90mg/kg/hour Placebo
Updated 1 time since 2026 Last updated: Jan 21, 2026 Started: Apr 1, 2026 Primary completion: Mar 24, 2027 Completion: May 31, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
A PHASE3 clinical study on Coronary Artery Bypass Graft Surgery(CABG) and Coronary Artery Disease (CAD), this trial is actively recruiting participants. The trial is conducted by CR2O B.V. and has accumulated 1 data snapshot since 2026. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Status Flow
Change History
1 version recorded Not Yet Recruiting — PHASE3
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- CR2O B.V.
- EBI Anti Sepsis BV
Data source: EBI Anti Sepsis BV
For direct contact, visit the study record on ClinicalTrials.gov .